---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-25-000058"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:41:32.317494+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q1 total revenue $59.6M (+63% YoY); software rev $48.8M; maintains FY guidance

## Summary
- Software revenue $48.8M (+46% YoY); drug discovery revenue $10.7M (+237%) incl $5.7M from Novartis collaboration.
- GAAP net loss $59.8M vs $54.7M; non-GAAP net loss improved to $46.7M from $62.4M.
- FY 2025 guidance reaffirmed: software rev growth 10-15%, drug discovery rev $45-50M, opex growth <5%.
- Initial Phase 1 data for SGR-1505 (MALT1 inhibitor) expected in June; SGR-2921 (CDC7) and SGR-3515 (Wee1/Myt1) data in H2 2025.
- Bridget van Kralingen appointed to Board of Directors; predictive toxicology initiative on track for H2 2025 launch.

## SEC filing metadata
- accession: 0001490978-25-000058
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097825000058/0001490978-25-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097825000058/sdgr-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-25-000058
- JSON: https://secwatch.observer/filing/0001490978-25-000058.json
- Plain text: https://secwatch.observer/filing/0001490978-25-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.